EXPLORER-HCM Trial: Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten is a novel cardiac-specific myosin ATPase inhibitor. It specifically reduces excessive cross-bridging with actin, which …
Mavacamten is a novel cardiac-specific myosin ATPase inhibitor. It specifically reduces excessive cross-bridging with actin, which …